Cardiac Safety Research Consortium

  • This field is for validation purposes and should be left unchanged.
Focused multiracial corporate business team people brainstorm on marketing plan financial report gather at office table meeting, diverse serious colleagues group discuss paperwork engaged in teamwork
Our Impact > Think Tanks

Agenda and Slides July 29, 2013

Trans-Radial Education and Therapeutics (TREAT) IV

Fourth Thinktank on Novel Research Infrastructure To Study Access Site & Bleeding Safety of Anti-Thrombotic Drugs

Monday July 29, 2013

FDA Headquarters

White Oak, Maryland

07:30-08:00  Arrival & Continental Breakfast

08:00-08:15:  Welcome & Introductions

08:15-10:00:  Plenary Session:  Novel Infrastructure for Clinical Trials & Innovation

·         Pre-competitive Collaboration Through Public-Private Partnerships:  The Key to Novel Research Infrastructure- Mitchell Krucoff, MD

·         Infrastructure & Innovation:  An Pre-Market FDA View- Bram Zuckerman, MD

·         Infrastructure & Innovation for Patient-Centered Device Surveillance- Danica Marinac-Dabic, MD, PhD

·               Embedding Clinical Interventions Into Observational Trials:  An NHLBI View- Larissa Aviles Santa, MD 

 ·         Leveraging Operational Cardiovascular Registries:  An ACC View- Ralph Brindis, MD

·         Competitive Industry Needs & Research Infrastructure:  Is Partnering Possible?- Robert “Chip” Hance, MD

·         Open Discussion

Lead Discussants 

10:00-10:30  Break

10:30-12:00:  SAFE PCI For Women

·          Update on SAFE PCI for Women- Sunil Rao, MD

·         SAFE PCI for Women:  ACC-NCDR View- Fran Fiocchi, MPH

·         SAFE PCI for Women:  Investigator View- Prashant Kaul, MD, FACC, FSCAI

·         SAFE PCI for Women:  FDA OWH View- Helen Barr, MD

·         SAFE PCI for Women:  Device Industry View- David Rutledge, PharmD

·         SAFE PCI for Women:  Pharma Industry View- Mark Effron, MD

·         Open Discussion

Lead Discussants

12:00-13:00  Lunch Break

13:00-14:45  SAFE STEMI for Seniors

·          STEMI, Bleeding & Outcomes in Seniors:  What Are the Issues?- Ron Waksman, MD and Joshua P, Loh, MD

·          TRI vs. TFA in STEMI:  Should We Randomize?- Ajay J. Kirtan, MD, SM

·          SAFE STEMI for Seniors:  NIH Application- Sunil Rao, MD

·         Open Discussion

Lead Discussants

14:45-15:15  Break

15:15-16:45  Operational Challenges for Novel Research Infrastructure

·           Data Quality & Monitoring Using NCDR for IDE:  – ACC View- Kathleen Hewitt, MSN, RN, AACC

·           Data Quality & Monitoring Using NCDR:  FDA View- Andrew Farb, MD and Dorothy Abel, BSBME

·           Accelerating CMS Outcomes Data to Near Real Time:  Challenges & Solutions- Rosemarie Hakim, PhD

·          Validating CMS Outcomes for IDE and IND Clinical Trials –J Matthew Brennan, MD, MPH

·          Open Discussion

Lead Discussants

Closing Comments